survodutide vs retatrutide Efficacy and Safety of GLP‐1 Receptor Agonists, Dual Agonists, and for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA - Sinha - 2025 - Obesity Survodutide vs Retatrutide vs Tirzepatide

Devirian TA, Volpe SL

AMA passes resolution calling for expanded access to anti-obesity medications

Antioxidant properties of UA Several clinical studies have found a relationship between high levels of UA and endothelial damage (the first critical step towards developing atherosclerosis), hypertension, and cardiovascular disease due to the pro-oxidative properties of UA

It is a dual GIP and GLP-1 receptor agonist, meaning it targets both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors

This combination reduced HVPG by 18.9% versus 12.5% with carvedilol alone, attenuated postprandial endothelial dysfunction, and decreased proinflammatory cytokines (IL-6, MCP-1)